Physician profile
James Bailey
NPI 1194112375
$2,251.97
in general payments reported to CMS, 2019-2025
20 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $47.34 · 2021: $218 · 2022: $191 · 2023: $449 · 2024: $659 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $701.14 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $335.19 | 2020-2025 | Repatha, Evenity, Otezla |
| Abbott Laboratories | $235.61 | 2021-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $164.81 | 2023 | Mounjaro, Jardiance, Emgality |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $128.76 | 2019 | |
| Allergan, INC. | $108.24 | 2019 | |
| Mayne Pharma Commercial LLC | $90.42 | 2024-2025 | |
| Novo Nordisk INC | $84.10 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $70.51 | 2023 | |
| Kyowa Kirin, INC. | $59.95 | 2024 | |
| Axsome Therapeutics, INC. | $59.37 | 2024 | Auvelity |
| Alexion Pharmaceuticals, INC. | $53.46 | 2019 | |
| Acadia Pharmaceuticals INC | $39.75 | 2025 | Daybue |
| Sumitomo Pharma America, INC. | $36.79 | 2023 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $17.60 | 2025 | Glassia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.62 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.77 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.59 | 2023 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $14.00 | 2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $7.29 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.